Document:

exv10w2

Exhibit 10.2

EXECUTION VERSION

AMENDMENT NO. 1 TO CREDIT AND GUARANTY AGREEMENT

          AMENDMENT NO. 1 TO CREDIT AND GUARANTY AGREEMENT, dated as of August 10, 2011 (this “Amendment
No. 1”), by and among VALEANT PHARMACEUTICALS INTERNATIONAL, a Delaware corporation (“Borrower”),
VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the federal laws of
Canada (“Parent”), certain Subsidiaries of Parent, as Guarantors, Goldman Sachs Lending Partners
LLC, as Administrative Agent (“Administrative Agent”), Swing Line Lender and Collateral Agent under
the Credit Agreement (as defined below), and the Requisite Lenders.

W I T N E S S E T H:

          WHEREAS, the Borrower, the Parent, the Administrative Agent, the Guarantors party thereto from
time to time and each lender from time to time party thereto (the “Lenders”) have entered into a
Credit and Guaranty Agreement, dated as of June 29, 2011 ( the “Original Credit Agreement”)
(capitalized terms not otherwise defined in this Amendment No. 1 have the same meanings as
specified in the Credit Agreement (as defined in Section 1 below));

          WHEREAS, on the date hereof, the Borrower, the Parent, the Guarantors, the Administrative
Agent, the Term Lenders (as defined below), and the Requisite Lenders (as defined in the Original
Credit Agreement) desire to amend and restate the Original Credit Agreement to, among other things,
(i) provide for Term Loans thereunder, (ii) modify certain covenants and (iii) make certain other
modifications as set forth in the Credit Agreement;

          WHEREAS, each financial institution identified on Schedule A hereto as a “Term Lender” (each,
a “Term Lender”) has agreed severally, on the terms and conditions set forth herein and in the
Credit Agreement, to make Term Loans and to become a “Term Lender” for all purposes under the
Credit Agreement;

          WHEREAS, pursuant to Section 10.5 of the Original Credit Agreement, the consent of the
Requisite Lenders (as defined in the Original Credit Agreement and before giving effect to the Term
Loan Commitments contemplated by this Amendment No. 1) is required for the effectiveness of this
Amendment No. 1; and

          WHEREAS, the Administrative Agent, the Collateral Agent, the Credit Parties, each Term Lender
and the other Lenders signatory hereto are willing to so agree, subject to the conditions set forth
herein.

          NOW, THEREFORE, in consideration of the premises and for other good and valuable
consideration, the sufficiency and receipt of all of which is hereby acknowledged, the parties
hereto hereby agree as follows:

SECTION 1. Amendment and Restatement.

          Effective as of the Restatement Date, and subject to the terms and conditions set forth herein
and in the Credit Agreement, upon the satisfaction of the conditions in Section 3 herein, the
parties hereto agree that (i) the Original Credit Agreement is hereby amended and restated in the
form of Annex A hereto (the Original Credit Agreement, as so amended and restated, being
referred to as the “Credit Agreement”), (ii) the Schedules attached to the Credit Agreement shall
replace in their entirety the corresponding Schedules attached to the Original Credit Agreement, or
constitute new Schedules to the

 

 

Credit Agreement, as applicable and (iii) the Exhibits attached to the Credit Agreement shall
replace in their entirety the corresponding Exhibits attached to the Original Credit Agreement, if
any, or constitute new Exhibits to the Credit Agreement, as applicable.

SECTION 2. Term Lenders.

          Each Term Lender hereby agrees, on the terms and conditions set forth herein and in the Credit
Agreement, to make Term Loans to the Borrower on or after the Restatement Date in accordance with
Section 2.1 of the Credit Agreement. The Term Lenders shall, effective on the Restatement Date,
become party to the Credit Agreement as “Lenders”.

SECTION 3. Effectiveness.

          (a) This Amendment No. 1 shall become effective on and as of the date (such date the
“Execution Date”) on which this Amendment No. 1 shall have been executed and delivered by (A) the
Borrower, Parent and the other Credit Parties, (B) each Term Lender, (C) Lenders constituting the
Requisite Lenders under Section 10.5 of the Original Credit Agreement (before giving effect to the
Term Loan Commitments contemplated by this Amendment No. 1), and (D) the Administrative Agent (it
being understood and agreed that Sections 1 and 2 of this Amendment No. 1 shall not become
effective until each of the conditions set forth in Section 3.1 of the Credit Agreement has been
satisfied).

          (b) The provisions of Sections 1 and 2 of this Amendment No. 1 and the Credit Agreement shall
become effective on the date (such date, the “Restatement Date”) on which each of the conditions
set forth in Section 3.1 of the Credit Agreement has been satisfied in accordance with the terms
thereof.

SECTION 4. Representations and Warranties.

          By its execution of this Amendment No. 1, each of the Borrower and Parent hereby represents
and warrants to the Agents and the Lenders that:

     (A) this Amendment No. 1 has been duly authorized, executed and delivered by it and
constitutes a legal, valid and binding obligation of each Credit Party hereto, enforceable
against such Credit Party in accordance with its terms, except as such enforceability may be
limited by bankruptcy, insolvency, reorganization, receivership, moratorium or other Laws
affecting creditors’ rights generally and by general principles of equity;

     (B) the execution, delivery and performance by Credit Parties of this Amendment No. 1
and the other Credit Documents to which they are parties and the consummation of the
transactions contemplated by this Amendment No. 1 and the other Credit Documents do not and
will not (a) violate (i) any provision of any Applicable Law, (ii) any of the Organizational
Documents of Parent, Borrower or any of their respective Subsidiaries, or (iii) any order,
judgment or decree of any court or other agency of government binding on Parent, Borrower or
any of their respective Subsidiaries, except with respect to clauses (i) and (iii) to the
extent that such violation could not reasonably be expected to have a Material Adverse
Effect; (b) conflict with, result in a breach of or constitute (with due notice or lapse of
time or both) a default under any Contractual Obligation of Parent, Borrower or any of their
respective Subsidiaries, except to the extent that such conflict, breach or default could
not reasonably be expected to have a Material Adverse Effect; (c) result in or require the
creation or imposition of any Lien upon any of the properties or assets of Parent, Borrower
or any of their respective Subsidiaries (other than any Liens created under any of the
Credit Documents in favor of Collateral Agent, on behalf of Secured Parties); or

-2-

 

(d) require any approval of stockholders, members or partners or any approval or
consent of any Person under any Contractual Obligation of Parent, Borrower or any of their
respective Subsidiaries, except for such approvals or consents which will be obtained on or
before the Closing Date and disclosed in writing to Lenders and except for any such approval
or consent the failure of which to obtain could not reasonably be expected to have a
Material Adverse Effect;

     (C) each of the representations and warranties contained in Section 4 of the Credit
Agreement is true as of the Execution Date and Restatement Date; and

     (D) there is no Default or Event of Default as of the Execution Date or Restatement
Date.

SECTION 5. Amendment, Modification and Waiver.

          This Amendment No. 1 may not be amended, modified or waived except in accordance with Section
10.5 of the Credit Agreement.

SECTION 6. Reference to and Effect on the Original Credit Agreement and the Credit
Documents.

          On and after the Restatement Date, each reference in the Original Credit Agreement or any
other Credit Document to “this Agreement,” “hereunder,” “hereof” or words of like import referring
to the Original Credit Agreement shall mean and be a reference to the Credit Agreement, as amended
by this Amendment No. 1 (i.e., the Credit Agreement).

SECTION 7. Reaffirmation and Grant.

          (a) Each Credit Party hereby expressly acknowledges the terms of this Amendment No. 1 and
reaffirms, as of the date hereof, the covenants and agreements contained in each Credit Document to
which it is a party, including, in each case, such covenants and agreements as in effect
immediately after giving effect to this Amendment No. 1 and the transactions contemplated hereby.

          (b) Each Credit Party, by its signature below, hereby affirms and confirms (1) its
obligations under each of the Credit Documents to which it is a party, and (2) the pledge of and/or
grant of a security interest in its assets as Collateral to secure such Obligations, all as
provided in the Collateral Documents as originally executed, and acknowledges and agrees that such
guarantee, pledge and/or grant continue in full force and effect in respect of, and to secure, such
Obligations under the Credit Agreement and the other Credit Documents.

          (c) In addition to, and not in lieu of, any other Liens for the benefit of the Lenders, as
security for the payment or performance, as the case may be, in full of the Secured Obligations (as
such term is defined in the Pledge and Security Agreement), including the Guarantees, each Grantor
(as such term is defined in the Pledge and Security Agreement) hereby grants security interests to
the Collateral Agent for the benefit of the Secured Parties (as such term is defined in the Pledge
and Security Agreement) in all right, title or interest in or to any and all of the Collateral (as
such term is defined in the Pledge and Security Agreement), whether now owned or hereafter
acquired.

          (d) Each Grantor hereby authorizes the filing of any financing statements or continuation
statements, and amendments to financing statements, in any jurisdictions and with any filing
offices as the Collateral Agent may determine, in its sole discretion, are necessary or advisable
to perfect the security interest granted to the Collateral Agent in connection with the Credit
Agreement. Such financing statements may contain an indication or description of collateral that
describes such property in any manner as

-3-

 

the Collateral Agent may determine, in its sole discretion, is necessary, advisable or prudent to
ensure the perfection of the security interest in the collateral granted to the Collateral Agent in
connection with this Agreement, including describing such property as “all assets” or “all personal
property,” and “whether now owned or at any time hereafter acquired” or “now has or at any time in
the future may acquire any right, title or interest” or words of similar import.

SECTION 8. Entire Agreement.

          This Amendment No. 1, the Credit Agreement and the other Credit Documents constitute the
entire agreement among the parties hereto with respect to the subject matter hereof and thereof and
supersede all other prior agreements and understandings, both written and verbal, among the parties
hereto with respect to the subject matter hereof. Except as expressly set forth herein, this
Amendment No. 1 shall not by implication or otherwise limit, impair, constitute a waiver of, or
otherwise affect the rights and remedies of any party under, the Original Credit Agreement, nor
alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or
agreements contained in the Original Credit Agreement, all of which are ratified and affirmed in
all respects and shall continue in full force and effect. It is understood and agreed that each
reference in each Credit Document to the Credit Agreement, whether direct or indirect, shall
hereafter be deemed to be a reference to the Credit Agreement as amended hereby and that this
Amendment No. 1 is a Credit Document.

SECTION 9. Governing Law.

          THIS AMENDMENT NO. 1 AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED
BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
SECTION 10.15 OF THE CREDIT AGREEMENT IS HEREBY INCORPORATED BY REFERENCE INTO THIS AMENDMENT NO. 1
AND SHALL APPLY HERETO.

SECTION 10. Severability.

          In case any provision in or obligation hereunder shall be invalid, illegal or unenforceable in
any jurisdiction, the validity, legality and enforceability of the remaining provisions or
obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be
affected or impaired thereby.

SECTION 11. Counterparts.

          This Amendment No. 1 may be executed in any number of counterparts, each of which when so
executed and delivered shall be deemed an original, but all such counterparts together shall
constitute but one and the same instrument. Delivery of an executed counterpart to this Amendment
No. 1 by facsimile transmission or other electronic transmission shall be effective as delivery of
a manually signed counterpart of this Amendment No. 1.

-4-

 

          IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute
and deliver this Amendment No. 1 as of the date first written above.

	 	 	 	 	 
	 	VALEANT PHARMACEUTICALS INTERNATIONAL

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	ATON PHARMA, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	CORIA LABORATORIES, LTD.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	DOW PHARMACEUTICAL SCIENCES, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President & Chief Operating Officer	 
	 

S-1 

 

	 	 	 	 	 
	 	VALEANT PHARMACEUTICALS NORTH AMERICA LLC

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	DR. LEWINN’S PRIVATE FORMULA INTERNATIONAL, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	OCEANSIDE PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	PRINCETON PHARMA HOLDINGS, LLC

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	PRIVATE FORMULA CORP.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	RENAUD SKIN CARE LABORATORIES, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 

S-2 

 

	 	 	 	 	 
	 	VALEANT BIOMEDICALS, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	BIOVAIL AMERICAS CORP.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	PRESTWICK PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/
Rajiv De Silva	 
	 	 	Name:  	Rajiv De Silva	 
	 	 	Title:  	President	 
	 
	 	BIOVAIL HOLDINGS INTERNATIONAL SRL

 	 
	 	By:  	/s/ Alex Matheson on behalf of
Richard K. Masterson	 
	 	 	Name:  	Richard K. Masterson	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	VALEANT INTERNATIONAL (BARBADOS) SRL

 	 
	 	By:  	/s/ Alex Matheson on behalf of
Richard K. Masterson	 
	 	 	Name:  	Richard K. Masterson	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL

 	 
	 	By:  	/s/ Alex Matheson on behalf of
Richard K. Masterson	 
	 	 	Name:  	Richard K. Masterson	 
	 	 	Title:  	President & Chief Operating Officer	 
	 
	 	HYTHE PROPERTY INCORPORATED

 	 
	 	By:  	/s/ Alex Matheson on behalf of
Richard K. Masterson	 
	 	 	Name:  	Richard K. Masterson	 
	 	 	Title:  	President & Chief Operating Officer	 

	 	 	 	 	 
	Each Signature in the Presence of:

 	 	 
	/s/ Bruce Goins
 	 	 
	Name:  	Bruce Goins 	 	 
	Occupation:  	Vice President, Finance 	 	 
	Address:  	Valeant International (Barbados) SRL 	 	 
	 

S-3 

 

	 	 	 	 	 
	 	VALEANT CANADA GP LIMITED

 	 
	 	By:  	/s/
Robert R. Chai-Onn	 
	 	 	Name:  	Robert R. Chai-Onn	 
	 	 	Title:  	Vice President	 
	 
	 	VALEANT CANADA LP by its sole general partner,

VALEANT CANADA GP LIMITED

 	 
	 	By:  	/s/
Robert R. Chai-Onn	 
	 	 	Name:  	Robert R. Chai-Onn	 
	 	 	Title:  	Director	 
	 
	 	V-BAC HOLDING CORP.

 	 
	 	By:  	/s/
Robert R. Chai-Onn	 
	 	 	Name:  	Robert R. Chai-Onn	 
	 	 	Title:  	Director	 
	 

S-4 

 

	 	 	 	 	 
	 	GOLDMAN SACHS LENDING PARTNERS LLC, 

individually as Administrative Agent, Collateral Agent and Swing Line Lender

 	 
	 	By:  	/s/
Robert Ehudin	 
	 	 	Name:  	Robert Ehudin	 
	 	 	Title:  	Authorized Signatory	 
	 
	 	GOLDMAN SACHS BANK USA, 

as a Lender,

 	 
	 	By:  	/s/
Robert Ehudin	 
	 	 	Name:  	Robert Ehudin	 
	 	 	Title:  	Authorized Signatory	 

S-5 

 

ANNEX A

CREDIT AGREEMENT

[See attached.]

Annex A

 

 

Schedule A

Term Lenders

Goldman Sachs Bank USA

Schedule Aexv10w3

Exhibit 10.3

EXECUTION VERSION

AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT

          AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT, dated as of August 12,
2011 (this “Amendment No. 1”), by and among VALEANT PHARMACEUTICALS INTERNATIONAL, a Delaware
corporation (“Borrower”), Goldman Sachs Lending Partners LLC, as Administrative Agent
(“Administrative Agent”), Swing Line Lender and Collateral Agent under the Credit Agreement (as
defined below), and the Requisite Lenders.

W I T N E S S E T H:

          WHEREAS, the Borrower, Valeant Pharmaceuticals International, Inc., the Administrative Agent,
the Guarantors party thereto from time to time and each lender from time to time party thereto (the
“Lenders”) have entered into an Amended and Restated Credit and Guaranty Agreement, dated as of
August 10, 2011 (the “Credit Agreement”) (capitalized terms not otherwise defined in this Amendment
No. 1 have the same meanings as specified in the Credit Agreement);

          WHEREAS, on the date hereof, the Borrower, the Administrative Agent and the Requisite Lenders
(as defined in the Credit Agreement) desire to amend the Credit Agreement as described in this
Amendment No. 1;

          WHEREAS, pursuant to Section 10.5 of the Credit Agreement, the consent of the Requisite
Lenders (as defined in the Credit Agreement) is required for the effectiveness of this Amendment
No. 1; and

          WHEREAS, the Administrative Agent, the Collateral Agent, the Borrower and the other Lenders
signatory hereto are willing to so agree, subject to the conditions set forth herein.

          NOW, THEREFORE, in consideration of the premises and for other good and valuable
consideration, the sufficiency and receipt of all of which is hereby acknowledged, the parties
hereto hereby agree as follows:

SECTION 1. Amendment.

          The Credit Agreement is hereby amended by deleting the last paragraph of Section 6.4 and
replacing it in the entirety with the following:

“Notwithstanding anything else in this Agreement to the contrary, Parent and Borrower shall not be
permitted to make any Restricted Junior Payment pursuant to Section 6.4(g) or (h) at any time Term
Loan Commitments or Term Loans are outstanding under this Agreement, other than Restricted Junior
Payments in an aggregate amount not exceeding $150,000,000 (it being understood that for purposes
of this Section 6.4, any Restricted Junior Payment in the form of the repurchase of shares shall be
deemed made on the trade date for such repurchase of shares (and not, for the avoidance of doubt,
on the settlement date)).”

 

 

SECTION 2. Effectiveness. This Amendment No. 1 shall become effective on and as of the
date (such date the “Effective Date”) on which this Amendment No. 1 shall have been executed and
delivered by (A) the Borrower, (B) Lenders constituting the Requisite Lenders under Section 10.5 of
the Credit Agreement, and (C) the Administrative Agent.

SECTION 3. Amendment, Modification and Waiver.

          This Amendment No. 1 may not be amended, modified or waived except in accordance with Section
10.5 of the Credit Agreement.

SECTION 4. Reference to and Effect on the Credit Agreement and the Credit Documents.

          On and after the Effective Date, each reference in the Credit Agreement or any other Credit
Document to “this Agreement,” “hereunder,” “hereof” or words of like import referring to the Credit
Agreement shall mean and be a reference to the Credit Agreement, as amended by this Amendment No.
1.

SECTION 5. Entire Agreement.

          This Amendment No. 1, the Credit Agreement and the other Credit Documents constitute the
entire agreement among the parties hereto with respect to the subject matter hereof and thereof and
supersede all other prior agreements and understandings, both written and verbal, among the parties
hereto with respect to the subject matter hereof. Except as expressly set forth herein, this
Amendment No. 1 shall not by implication or otherwise limit, impair, constitute a waiver of, or
otherwise affect the rights and remedies of any party under, the Credit Agreement, nor alter,
modify, amend or in any way affect any of the terms, conditions, obligations, covenants or
agreements contained in the Credit Agreement, all of which are ratified and affirmed in all
respects and shall continue in full force and effect. It is understood and agreed that each
reference in each Credit Document to the Credit Agreement, whether direct or indirect, shall
hereafter be deemed to be a reference to the Credit Agreement as amended hereby and that this
Amendment No. 1 is a Credit Document.

SECTION 6. Governing Law.

          THIS AMENDMENT NO. 1 AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED
BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.
SECTION 10.15 OF THE CREDIT AGREEMENT IS HEREBY INCORPORATED BY REFERENCE INTO THIS AMENDMENT NO. 1
AND SHALL APPLY HERETO.

SECTION 7. Severability.

          In case any provision in or obligation hereunder shall be invalid, illegal or unenforceable in
any jurisdiction, the validity, legality and enforceability of the remaining provisions or
obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be
affected or impaired thereby.

SECTION 8. Counterparts.

          This Amendment No. 1 may be executed in any number of counterparts, each of which when so
executed and delivered shall be deemed an original, but all such counterparts together shall
constitute but one and the same instrument. Delivery of an executed counterpart to this Amendment
No. 1 by
facsimile transmission or other electronic transmission shall be effective as delivery of a
manually signed counterpart of this Amendment No. 1.

-2-

 

          IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized officer to execute
and deliver this Amendment No. 1 as of the date first written above.

	 	 	 	 	 
	 	VALEANT PHARMACEUTICALS INTERNATIONAL

 	 
	 	By:  	
/s/ Philip W. Loberg	 
	 	 	Name:  	Philip W. Loberg	 
	 	 	Title:  	SVP, Group Financial Controller	 
	 

S-1

 

	 	 	 	 	 
	 	GOLDMAN SACHS LENDING PARTNERS LLC,

individually as Administrative Agent, Collateral Agent

and Swing Line
Lender

 	 
	 	By:  	/s/
Robert Ehudin	 
	 	 	Name:  	Robert Ehudin	 
	 	 	Title:  	Authorized Signatory	 
	 

S-2

 

	 	 	 	 	 
	 	GOLDMAN SACHS BANK USA, as a Lender.

 	 
	 	By:  	/s/
Robert Ehudin	 
	 	 	Robert Ehudin 	 
	 	 	Authorized Signatory 	 
	 	 	 	 
	 

S-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]